Promotion of Intrathecal Baclofen by Medtronic limited
Published 9 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-march-2021/promotion-of-intrathecal-baclofen-by-medtronic-limited
SUMMARY REPORT FOR PUBLICATION
March 2021 Promotion of Intrathecal Baclofen by Medtronic limited
A member of the public complained about an advertisement that was shown on their LinkedIn feed about a generic Prescription Only Medicines (POM) to be used with an intrathecal injection device that could be viewed by members of the public in November 2020 by Medtronic Limited. The complainant alleged that POM was being promoted to the public, while linked pages were not clearly distinguished for Health Care Professionals.
MHRA upheld the complaint. Medtronic confirmed that they have put a hold on all promotional campaigns involving the SynchroMed II pump have removed the LinkedIn campaign including linked webpages within the campaign pages and are reviewing all current promotional materials and are reviewing patient webpages related to SynchroMed II pumps.